Sensipar® is indicated for the treatment of secondary
hyperparathyroidism in patients with Chronic Kidney Disease on dialysis.
Sensipar® is indicated for the treatment of hypercalcemia in patients with
Sensipar® lowers serum calcium. Significant reductions in calcium may lower the
threshold for seizures. Secondary hyperparathyroidism patients, particularly
those with a history of a seizure disorder, should be carefully monitored for
the occurrence of low serum calcium or symptoms of hypocalcemia. The most
commonly reported side effects were nausea and vomiting.
Mimpara® is the tradename for cinacalcet in Europe and
Sensipar® is the tradename for cinacalcet in the US. If you are a European
physician prescribing Mimpara® in Europe, please refer to the Mimpara®
More information is available at